CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-13 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Restricted Stock Units | −2,113 | 0 | ||
| 2026-10-13 | Kulkarni Samarth Chief Executive Officer | Option exercise | +8,333 | 263,834 | ||
| 2026-10-13 | Kulkarni Samarth Chief Executive Officer | Option exercise · Restricted Stock Units | −8,333 | 0 | ||
| 2026-10-06 | KASINGER JAMES R. General Counsel and Secretary | Option exercise 10b5-1 | +1,990 | $13.62 | $27K | 96,774 |
| 2026-10-06 | KASINGER JAMES R. General Counsel and Secretary | Sale 10b5-1 | −1,990 | $60.04 | $119K | 94,784 |
| 2026-10-06 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,990 | 81,242 | ||
| 2026-09-22 | KASINGER JAMES R. General Counsel and Secretary | Option exercise 10b5-1 | +10,400 | $13.62 | $142K | 105,184 |
| 2026-09-22 | KASINGER JAMES R. General Counsel and Secretary | Sale 10b5-1 | −10,400 | $60.24 | $626K | 94,784 |
| 2026-09-22 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,400 | 83,232 | ||
| 2026-09-17 | Behbahani Ali Director | Option exercise | +30,000 | $14.00 | $420K | 30,316 |
| 2026-09-17 | Behbahani Ali Director | Sale | −13,679 | $57.09 | $781K | 16,637 |
| 2026-09-17 | Behbahani Ali Director | Option exercise · Stock Option (Right to Buy) | −30,000 | 0 | ||
| 2026-08-07 | Prasad Raju Chief Financial Officer | Gift | −750 | 14,815 | ||
| 2026-06-05 | George Simeon Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | Fardis Maria Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | Fleming Harold Edward Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | Greene John Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | High Katherine A Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2026-06-05 | Mahatme Sandesh Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 |
Page 2 of 46 · 910 trades